Acticor Biotech: World's First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug
Source: finanznachrichten.de